<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00607672</url>
  </required_header>
  <id_info>
    <org_study_id>051170</org_study_id>
    <secondary_id>HL 085740-01</secondary_id>
    <nct_id>NCT00607672</nct_id>
  </id_info>
  <brief_title>The RAS, Fibrinolysis and Cardiopulmonary Bypass</brief_title>
  <official_title>The RAS, Fibrinolysis and Cardiopulmonary Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each year over a million patients worldwide undergo cardiac surgery requiring cardiopulmonary
      bypass (CPB).1 CPB is associated with significant morbidity including hemodynamic
      instability, the transfusion of allogenic blood products, and inflammation. Blood product
      transfusion increases mortality after cardiac surgery. Enhanced fibrinolysis contributes to
      increased blood product transfusion requirements in the perioperative period. CPB activates
      the kallikrein-kinin system (KKS), leading to increased bradykinin concentrations.
      Bradykinin, acting through its B2 receptor, stimulates the release of nitric oxide,
      inflammatory cytokines and tissue-type plasminogen activator (t-PA). Based on data indicating
      that angiotensin-converting enzyme (ACE) inhibitors reduce mortality in patients with
      coronary artery disease, many patients undergoing CPB are taking ACE inhibitors. While
      interruption of the renin-angiotensin system (RAS) reduces inflammation in response to CPB,
      ACE inhibitors also potentiate the effects of bradykinin and may augment B2-mediated change
      in fibrinolytic balance and inflammation. In contrast, angiotensin II type 1 receptor
      antagonism does not potentiate bradykinin and does not inhibit bradykinin metabolism.

      Studies in animals suggest that bradykinin receptor antagonism inhibits reperfusion-induced
      increases in vascular permeability and neutrophil recruitment.A randomized, placebo
      controlled clinical trial of a bradykinin B2 receptor antagonist demonstrated some effect on
      survival in patients with systemic inflammatory response syndrome and gram-negative sepsis.
      In addition, we and others have shown bradykinin B2 receptor antagonism reduces vascular t-PA
      release during ACE inhibition. The current proposal derives from data from our laboratory and
      others elucidating the role of the KKS in the inflammatory, hypotensive and fibrinolytic
      response to CPB. Specifically, we have found that CPB activates the KKS and that ACE
      inhibition and smoking further increases bradykinin concentrations. During CPB, bradykinin
      concentrations correlate inversely with mean arterial pressure and directly with t-PA.
      Moreover, we have found that bradykinin receptor antagonism attenuates protamine-related
      hypotension following CPB. The current proposal tests the central hypothesis that the
      fibrinolytic and inflammatory response to cardiopulmonary bypass differ during
      angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue-type Plasminogen Activator (t-PA) Antigen Response</measure>
    <time_frame>From the start of surgery until postoperative day 2</time_frame>
    <description>To compare the effects of angiotensin II type I (AT1) receptor antagonism or angiotensin-converting enzyme (ACE) inhibition versus placebo on the fibrinolytic responses to cardiopulmonary bypass (CPB) as measured by t-PA antigen response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasminogen Activator Inhibitor-1 (PAI-1) Response</measure>
    <time_frame>From the start of surgery until postoperative day 2</time_frame>
    <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the fibrinolytic responses to CPB as measured by PAI-1 response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-6 (IL-6) Response</measure>
    <time_frame>From the start of surgery until postoperative day 2</time_frame>
    <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-8 (IL-8) Response</measure>
    <time_frame>From the start of surgery until postoperative day 2</time_frame>
    <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-10 (IL-10) Response</measure>
    <time_frame>From the start of surgery until postoperative day 2</time_frame>
    <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by the IL-10 response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>First 24 hours after arrival in the intensive care unit</time_frame>
    <description>Blood loss over 24 hours as measured by chest tube output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-exploration for Bleeding</measure>
    <time_frame>From arrival in intensive care unit until discharge from hospital</time_frame>
    <description>The percentage of patients that were taken back to the operating room for re-exploration because of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Product Transfusion Requirement</measure>
    <time_frame>From the start of surgery until discharge from hospital</time_frame>
    <description>Percentage of patients that received blood product transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor Drug Use</measure>
    <time_frame>From the end of cardiopulmonary bypass until arrival in intensive care unit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Onset Atrial Fibrillation</measure>
    <time_frame>From arrival in intensive care unit until discharge from hospital</time_frame>
    <description>New onset atrial fibrillation based on electrocardiogram (ECG) rhythm strips with a duration longer than 10 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>From the start of surgery until postoperative day 3</time_frame>
    <description>Acute kidney injury (AKI) was defined according to Acute Kidney Injury Network (AKIN) criteria,specifically any increase in subject serum creatinine concentration of 50% or 0.3 mg/dL (26.5 umol/L) within 72 hours of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>From arrival in intensive care unit until discharge from hospital</time_frame>
    <description>New onset neurological deficit with a duration of longer than 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>From the start of surgery until discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angiotensin Converting Enzyme</condition>
  <condition>Angiotensin Receptor Blockers</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <condition>Fibrinolysis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients are randomized to placebo prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to Ramipril prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to Candesartan (ARB) prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>Candesartan 16mg/d</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion Criteria

          1. Subjects, 18 to 80 years of age, scheduled for elective cardiac surgery requiring CPB

          2. For female subjects, the following conditions must be met:

        postmenopausal for at least 1 year, or status-post surgical sterilization, or if of
        childbearing potential, utilizing adequate birth control and willing to undergo urine
        beta-hcg testing prior to drug treatment and on every study day

        Exclusion Criteria:

          1. Left ventricle ejection fraction less than 30%

          2. History of ACE inhibitor-induced angioedema

          3. Hypotension (systolic blood pressure &lt;100 mmHg and evidence of hypoperfusion)

          4. Hyperkalemia (baseline potassium &gt;5.0 mEq/L)

          5. Inability to discontinue current ACE inhibitor or AT1 receptor antagonist.

          6. Emergency surgery

          7. Impaired renal function (serum creatinine &gt;1.6 mg/dl)

          8. Pregnancy

          9. Breast-feeding

         10. Any underlying or acute disease requiring regular medication which could possibly pose
             a threat to the subject or make implementation of the protocol or interpretation of
             the study results difficult

         11. History of alcohol or drug abuse

         12. Treatment with any investigational drug in the 1 month preceding the study

         13. Mental conditions rendering the subject unable to understand the nature, scope and
             possible consequences of the study

         14. Inability to comply with the protocol, e.g. uncooperative attitude and unlikelihood of
             completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mias Pretorius, MBChB, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TN Valley Healthcare System</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Billings FT 4th, Balaguer JM, C Y, Wright P, Petracek MR, Byrne JG, Brown NJ, Pretorius M. Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass. Clin Pharmacol Ther. 2012 Jun;91(6):1065-73. doi: 10.1038/clpt.2011.356.</citation>
    <PMID>22549281</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>August 2, 2012</results_first_submitted>
  <results_first_submitted_qc>September 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2012</results_first_posted>
  <last_update_submitted>September 7, 2012</last_update_submitted>
  <last_update_submitted_qc>September 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Mias Pretorius</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Angiotensin Converting Enzyme</keyword>
  <keyword>Angiotensin Receptor Blockers</keyword>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Fibrinolysis</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult patients scheduled for elective cardiac surgery requiring cardiopulmonary bypass were recruited from the Vanderbilt surgery clinic between 2006 and 2011.</recruitment_details>
      <pre_assignment_details>Patients were excluded after enrollment if they met exclusion criteria, if surgery was canceled or if the patient changed his mind.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients are randomized to placebo prior to surgery</description>
        </group>
        <group group_id="P2">
          <title>Ramipril (ACEI)</title>
          <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
        </group>
        <group group_id="P3">
          <title>Candesartan (ARB)</title>
          <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients are randomized to placebo prior to surgery</description>
        </group>
        <group group_id="B2">
          <title>Ramipril (ACEI)</title>
          <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
        </group>
        <group group_id="B3">
          <title>Candesartan (ARB)</title>
          <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.14" spread="11.24"/>
                    <measurement group_id="B2" value="64.38" spread="10.35"/>
                    <measurement group_id="B3" value="67.05" spread="8.14"/>
                    <measurement group_id="B4" value="65.84" spread="10.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tissue-type Plasminogen Activator (t-PA) Antigen Response</title>
        <description>To compare the effects of angiotensin II type I (AT1) receptor antagonism or angiotensin-converting enzyme (ACE) inhibition versus placebo on the fibrinolytic responses to cardiopulmonary bypass (CPB) as measured by t-PA antigen response</description>
        <time_frame>From the start of surgery until postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Angiotensin-converting enzyme group</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Angiotensin receptor blocker group</description>
          </group>
        </group_list>
        <measure>
          <title>Tissue-type Plasminogen Activator (t-PA) Antigen Response</title>
          <description>To compare the effects of angiotensin II type I (AT1) receptor antagonism or angiotensin-converting enzyme (ACE) inhibition versus placebo on the fibrinolytic responses to cardiopulmonary bypass (CPB) as measured by t-PA antigen response</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.36" spread="1.45"/>
                    <measurement group_id="O2" value="14.05" spread="1.86"/>
                    <measurement group_id="O3" value="11.97" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60min of CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.65" spread="3.39"/>
                    <measurement group_id="O2" value="36.67" spread="7.26"/>
                    <measurement group_id="O3" value="24.89" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.56" spread="3.35"/>
                    <measurement group_id="O2" value="41.11" spread="3.37"/>
                    <measurement group_id="O3" value="31.47" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.25" spread="2.03"/>
                    <measurement group_id="O2" value="17.10" spread="1.38"/>
                    <measurement group_id="O3" value="15.75" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.56" spread="1.87"/>
                    <measurement group_id="O2" value="12.49" spread="0.93"/>
                    <measurement group_id="O3" value="12.89" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasminogen Activator Inhibitor-1 (PAI-1) Response</title>
        <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the fibrinolytic responses to CPB as measured by PAI-1 response</description>
        <time_frame>From the start of surgery until postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Angiotensin-converting enzyme group</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Angiotensin receptor blocker group</description>
          </group>
        </group_list>
        <measure>
          <title>Plasminogen Activator Inhibitor-1 (PAI-1) Response</title>
          <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the fibrinolytic responses to CPB as measured by PAI-1 response</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.14" spread="1.42"/>
                    <measurement group_id="O2" value="16.25" spread="2.70"/>
                    <measurement group_id="O3" value="18.28" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60min of CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.43" spread="1.63"/>
                    <measurement group_id="O2" value="19.41" spread="1.98"/>
                    <measurement group_id="O3" value="24.19" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.69" spread="3.78"/>
                    <measurement group_id="O2" value="41.62" spread="5.89"/>
                    <measurement group_id="O3" value="49.10" spread="7.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.83" spread="4.47"/>
                    <measurement group_id="O2" value="26.27" spread="4.50"/>
                    <measurement group_id="O3" value="21.70" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.59" spread="3.77"/>
                    <measurement group_id="O2" value="17.33" spread="3.77"/>
                    <measurement group_id="O3" value="13.4" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.84</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Loss</title>
        <description>Blood loss over 24 hours as measured by chest tube output</description>
        <time_frame>First 24 hours after arrival in the intensive care unit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients are randomized to placebo prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Loss</title>
          <description>Blood loss over 24 hours as measured by chest tube output</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437" spread="35"/>
                    <measurement group_id="O2" value="470" spread="59"/>
                    <measurement group_id="O3" value="511" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Re-exploration for Bleeding</title>
        <description>The percentage of patients that were taken back to the operating room for re-exploration because of bleeding</description>
        <time_frame>From arrival in intensive care unit until discharge from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients are randomized to placebo prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Re-exploration for Bleeding</title>
          <description>The percentage of patients that were taken back to the operating room for re-exploration because of bleeding</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Product Transfusion Requirement</title>
        <description>Percentage of patients that received blood product transfusion</description>
        <time_frame>From the start of surgery until discharge from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients are randomized to placebo prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Product Transfusion Requirement</title>
          <description>Percentage of patients that received blood product transfusion</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Packed red blood cells</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cryoprecipitate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>For plasma transfusion comparison. Ramipril and Candesartan versus placebo</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vasopressor Drug Use</title>
        <time_frame>From the end of cardiopulmonary bypass until arrival in intensive care unit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients are randomized to placebo prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Vasopressor Drug Use</title>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dobutamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="29.2"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mlrinone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norepinephrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="79.2"/>
                    <measurement group_id="O3" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epinephrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.27</p_value>
            <p_value_desc>Comparison for norepinephrine use</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Onset Atrial Fibrillation</title>
        <description>New onset atrial fibrillation based on electrocardiogram (ECG) rhythm strips with a duration longer than 10 seconds</description>
        <time_frame>From arrival in intensive care unit until discharge from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients are randomized to placebo prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>New Onset Atrial Fibrillation</title>
          <description>New onset atrial fibrillation based on electrocardiogram (ECG) rhythm strips with a duration longer than 10 seconds</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Kidney Injury</title>
        <description>Acute kidney injury (AKI) was defined according to Acute Kidney Injury Network (AKIN) criteria,specifically any increase in subject serum creatinine concentration of 50% or 0.3 mg/dL (26.5 umol/L) within 72 hours of surgery.</description>
        <time_frame>From the start of surgery until postoperative day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients are randomized to placebo prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Kidney Injury</title>
          <description>Acute kidney injury (AKI) was defined according to Acute Kidney Injury Network (AKIN) criteria,specifically any increase in subject serum creatinine concentration of 50% or 0.3 mg/dL (26.5 umol/L) within 72 hours of surgery.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="23.8"/>
                    <measurement group_id="O3" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke</title>
        <description>New onset neurological deficit with a duration of longer than 24 hours</description>
        <time_frame>From arrival in intensive care unit until discharge from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients are randomized to placebo prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <description>New onset neurological deficit with a duration of longer than 24 hours</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Hospital Stay</title>
        <time_frame>From the start of surgery until discharge from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients are randomized to placebo prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Patients are randomized to Candesartan 16mg/d (ARB) prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Hospital Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="0.5"/>
                    <measurement group_id="O2" value="6.3" spread="0.6"/>
                    <measurement group_id="O3" value="8.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-6 (IL-6) Response</title>
        <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-6</description>
        <time_frame>From the start of surgery until postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Angiotensin-converting enzyme group</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Angiotensin receptor blocker group</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-6 (IL-6) Response</title>
          <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-6</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.29" spread="1.25"/>
                    <measurement group_id="O2" value="9.33" spread="3.25"/>
                    <measurement group_id="O3" value="6.44" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.04" spread="28.19"/>
                    <measurement group_id="O2" value="167.51" spread="35.64"/>
                    <measurement group_id="O3" value="144.76" spread="29.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.96" spread="63.26"/>
                    <measurement group_id="O2" value="172.65" spread="68.93"/>
                    <measurement group_id="O3" value="218.16" spread="68.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.96" spread="28.79"/>
                    <measurement group_id="O2" value="144.67" spread="46.41"/>
                    <measurement group_id="O3" value="243.72" spread="117.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-8 (IL-8) Response</title>
        <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-8</description>
        <time_frame>From the start of surgery until postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Angiotensin-converting enzyme group</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Angiotensin receptor blocker group</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-8 (IL-8) Response</title>
          <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by IL-8</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.18" spread="3.77"/>
                    <measurement group_id="O2" value="11.86" spread="1.42"/>
                    <measurement group_id="O3" value="13.38" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.44" spread="15.06"/>
                    <measurement group_id="O2" value="80.07" spread="20.28"/>
                    <measurement group_id="O3" value="76.76" spread="18.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.18" spread="8.90"/>
                    <measurement group_id="O2" value="37.39" spread="6.04"/>
                    <measurement group_id="O3" value="37.11" spread="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.39" spread="5.55"/>
                    <measurement group_id="O2" value="28.06" spread="5.28"/>
                    <measurement group_id="O3" value="37.77" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-10 (IL-10) Response</title>
        <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by the IL-10 response</description>
        <time_frame>From the start of surgery until postoperative day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
          <group group_id="O2">
            <title>Ramipril (ACEI)</title>
            <description>Angiotensin-converting enzyme group</description>
          </group>
          <group group_id="O3">
            <title>Candesartan (ARB)</title>
            <description>Angiotensin receptor blocker group</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-10 (IL-10) Response</title>
          <description>To compare the effects of AT1 receptor antagonism or ACE inhibition versus placebo on the inflammatory response to CPB as measured by the IL-10 response</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre CPB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.45" spread="0.47"/>
                    <measurement group_id="O2" value="5.36" spread="0.80"/>
                    <measurement group_id="O3" value="4.21" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="461.90" spread="84.64"/>
                    <measurement group_id="O2" value="815.74" spread="273.29"/>
                    <measurement group_id="O3" value="749.56" spread="199.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.70" spread="6.91"/>
                    <measurement group_id="O2" value="26.89" spread="4.64"/>
                    <measurement group_id="O3" value="22.55" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.74" spread="3.09"/>
                    <measurement group_id="O2" value="14.59" spread="3.16"/>
                    <measurement group_id="O3" value="14.26" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The patients were followed from the day of surgery until discharge from hospital, an average of 8 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
        <group group_id="E2">
          <title>Ramipril (ACEI)</title>
          <description>Angiotensin-converting enzyme group</description>
        </group>
        <group group_id="E3">
          <title>Candesartan (ARB)</title>
          <description>Angiotensin receptor blocker group</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>In-hospital mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>New onset atrial fibrillation</sub_title>
                <description>Patient with pre-existing AF were excluded</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Re-exploration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>Acute kidney injury (AKI) was defined according to Acute Kidney Injury Network (AKIN) criteria, specifically any increase in subject serum creatinine concentration of 50% or 0.3 mg/dL (26.5 umol/L) within 72 hours of surgery.</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We cannot exclude the possibility that our results may have been different if we studied a homogenous surgery population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mias Pretorius</name_or_title>
      <organization>Vanderbilt University School of Medicine</organization>
      <phone>16153430665</phone>
      <email>mias.pretorius@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

